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Summary
Background: Whereas until 2003 Lympho-
granuloma venereum (LGV) was rare in industri-
alised countries, there have been increasing re-
ports of cases of LGV proctitis in men having sex
with men (MSM) over the last six years in Europe,
America and Australia.
Patients and methods: After the alarming mes-
sage from the Netherlands in 2003, physicians in
a dermatological and STI private clinic in Zurich
started examining rectal swabs from patients with
proctitis for LGV serovars of C. trachomatis on a
regular basis. A test system based on PCR with se-
quencing and databank comparison was used.
Clinical files of all patients with proctitis observed
in this time period were examined.
Results: Since 2003 twelve cases of proctitis, all
in MSM, caused by the LGV serovar L2 C. tracho-
matis were observed.Of the overall 11 patients the
majority were HIV positive and only 2 were HIV
negative. Only one patient reported previous sex-
ual contacts outside Europe (Thailand) as the
likely place of infection. The clinical presentation
was characterised by anorectal pain, discharge, te-
nesmus and change in stool frequency. Four pa-
tients were successfully treated with a single dose
of 1 g azithromycin. In all seven cases treated with
doxycycline 2x100 mg for 10–20 days clinical cure
and a negative PCR result after treatment were
observed, except for one patient lost to follow-up.
Conclusions: Zurich has not been spared by the
recent outbreaks of LGV proctitis in MSM. Ano-
rectal LGV infections may progress to severe de-
structive changes, with formation of granulomas,
strictures, and perirectal abscesses. Increased
awareness of this problem and establishment of
reliable diagnostic tools are required.
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Introduction
Chlamydia trachomatis is an obligate intracellu-
lar parasite that is subdivided into numerous se-
rovars or serotypes [1]. Serotypes A–C cause tra-
choma, while serotypes D–K are responsible for a
wide spectrum of diseases including cervicitis,
urethritis and endometritis. Lymphogranuloma
venereum (LGV), or Nicolas-Favre disease, is a
sexually transmitted infection (STI) caused by C.
trachomatis serovar L1, L2, or L3 [2]. Unlike other
chlamydial urogenital infections that are generally
restricted to epithelial surfaces, L serovars are in-
vasive, can cause severe inflammation, often with
systemic symptoms, and have a preference for
lymphatic tissue. LGV typically occurs in both
sexes and presents with one or more genital ulcers
or papules, followed by the development of unilat-
eral or bilateral, fluctuant, inguinal lymphadeno-
pathy (buboes) in the second stage and by lymphoe-
dema, abscesses, granulomas and strictures in the
third stage [3]. Before 2003 LGV was considered
to be a “tropical” disease, endemic in parts of Af-
rica, Latin America, and Asia, but rare in Western
industrialised countries. In 2003 an outbreak of
LGV in 13 MSM was reported in Rotterdam,
Netherlands [4]. Since then further reports of out-
breaks of LGV in MSM from The Netherlands,
Belgium [5], France [6], Germany [7, 8], Sweden
[9], the United Kingdom [10],NorthAmerica [11]
and Australia [12] have followed. One confirmed
case of LGV was reported in Geneva in 2005 [13].
To date,most LGV outbreaks have beencaused by
the strain L2, have occurred in MSM and have
manifested as proctitis.
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This study is based on information obtained from the
clinical files of patients diagnosed with LGV in a gay-
friendly dermatological and STI private clinic in Zurich
in the time period 2003–2007.After the alarming message
from the Netherlands in 2003 the physicians in this clinic
started regularly examining rectal swabs from patients
with proctitis for LGV serovars of C. trachomatis. Clinical
files, including detailed clinical history, epidemiologically
relevant information, symptoms,manifestation, treatment
regimens and outcome were reviewed for all patients ob-
served with proctitis in this time period.C. trachomatiswas
detected in rectal swabs by a test system based on PCR
with sequencing and databank comparison [14].
Patients and methods
Results
The charts of 262 patients who presented with
the chief complaint of anal pain and/or discharge
and were examined by rectal swab for C. trachoma-
tis PCR between 2003 and 2007 were reviewed.Of
these swabs, 49 were positive for C. trachomatis.
Various serotypes were found: 13 samples (11 pa-
tients) with serotype L2, 11 samples (10 patients)
with serotype D, 15 samples with serotype G and
10 samples with serotype J.Of the 11 patients with
proctitis due to C. trachomatis serotype L2, nine
were HIV positive and two HIV negative (table
N 1).Two patients hadNeisseria gonorrhoeae co-in-
fection and one patient was diagnosed with con-
comitant syphilis. All of the patients with serotype
L2 were MSM. Most of the patients reported the
likely place of infection to be in Western Euro-
pean cities: London, Amsterdam, Brussels, Berlin,
Frankfurt and Zurich. Only one patient reported
previous sexual contacts outside Europe (Thai-
land) as the most likely place of infection. The
clinical presentation was characterised by anorec-
tal pain, discharge, tenesmus and change in stool
frequency. In seven cases the discharge was puru-
lent, in two cases it was purulent and haemor-
rhagic, in a further two cases it was serous and in
one haemorrhagic. One patient with purulent
proctitis developed a perirectal abscess. Lymph-
adenopathy was not a feature in any of the cases.
At the time when treatment was prescribed no in-
formation on the causative microorganism was yet
available. Four cases were treated with a single
dose of 1 g azithromycin, achieving clinical cure
and negative PCR control one month later. Two
patients were initially treated with 500mg azithro-
mycin daily over three days.One failed to respond.
In the second the symptoms improved, but one
month later he presented with recurrent anorectal
pain and C. trachomatis serotype L2 was again de-
tected. Seven cases (including the two that did not
respond to azithromycin) were treated with doxy-
cycline 2 x 100 mg for 10–20 days. Clinical cure
was observed and confirmed by control PCR ex-
amination after treatment in all six cases available
for follow-up.
Table 1
Overview of patient characteristics, treatment and outcome.Total number of positive samples is 13, obtained from 11 patients (patient 2 and patient
4 had two symptomatic episodes and 2 positive samples each).
Patient Diagnosis Clinical presentation
Presumed place
of infection Treatment Comorbidities Follow-up
1 03/2003 Purulent proctitis unknown Azithromycin 1g HIV neg. PCR neg 4/03
2
04/2003 Purulent and hemorrhagic
proctitis
London Azithromycin 1g HIV pos. PCR neg 4/03
10/2003 Purulent proctitis London Azithromycin 1g PCR neg 9/05
3 05/2003 Hemorrhagic proctitis Thailand Azithromycin 500 mg/d for 3 days,
Doxycyclin 100 mg bid for 10 days
HIV pos. PCR neg 07/03
4
11/2003 Purulent proctitis Amsterdam Azithromycin 500 mg/d for 3 days HIV neg., Syphilis
12/2003 Purulent proctitis Doxycyclin 100 mg bid for 10 days PCR neg 7/05
5 11/2003 Purulent proctitis Brussels Ofloxacin 300 mg bid for 7 days HIV pos.,
N. gonorrhoe pos. PCR neg 3/04
6 04/2005 Proctitis, non-purulent
(serous)
Berlin Azithromycin 1g HIV pos. PCR neg 07/05
7 07/2005 Purulent proctitis Zürich Doxycyclin 100 mg bid for 12 days HIV pos. lost for follow-up
8 06/2006 Proctitis, non-purulent
(serous)
Berlin Doxycyclin 100 mg bid for 10 days HIV pos. PCR neg. 08/06
9 03/2007 Purulent proctitis Zürich Doxycyclin 100 mg bid for 20 days HIV pos.,
N. gonorrhoe pos. PCR neg. 04/2007
10 04/2007 Purulent proctitis, perirectal
abscess
Frankfurt Doxycyclin 100 mg bid for 20 days HIV pos PCR neg 05 2007
11 08/2007 Purulent and hemorrhagic
proctitis
Frankfurt Doxycyclin 100 mg bid for 20 days HIV pos. PCR neg 10/07
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Rectal infections with LGV immunotypes of
C. trachomatis have been recognised since 1936
[15] but were rarely diagnosed until 2003. Early
sporadic reports of LGV in MSMare found in the
literature. Although LGV has been known to af-
fect the rectum in the late stages of classical dis-
ease, proctitis became recognised as the major
manifestation of LGV in MSM following case se-
ries such as those identified in Seattle [16, 17] and
San Francisco [18, 19] in the late 1970s and early
1980s. In 2003 an outbreak of LGV in 13 MSM
was reported in Rotterdam, Netherlands. Since
then further reports of outbreaks of LGV inMSM
from many other European countries, North
America and Australia have followed. To date,
most LGV cases have been caused by the L2
strain. Another feature of these new outbreaks is
the fact that most cases have occurred inMSM and
that most patients have presented with the symp-
toms of anal discharge and proctitis. The mode of
transmission of LGV inMSM is only partly under-
stood. Almost all reported cases of LGV in MSM
present as proctitis, and even though a series of
13 MSM presenting with inguinogenital LGV
lesions has recently been published [20], inguino-
genital disease in this population remains very rare
and suggests rectum-to-rectum transmission. Case
finding studies [21, 22] suggest that involvement of
an asymptomatic reservoir of LGV is very unlikely.
HIV infection has been reported to be present in
over 70% of patients with LGV proctitis and rep-
resents the most important risk factor [10], a find-
ing corroborated by our study. On the other hand,
there is no evidence that LGV should be regarded
as an opportunistic infection. In our series the
HIV infection preceded the LGV proctitis in all
cases. All HIV positive patients were receiving
HAART and had stable T-cell counts without
clinical signs of immunosuppression (data not
shown).The high degree of coinfection with HIV
and C. trachomatis, serovar L2 is not fully clear, but
risk sexual behaviour seems to play an important
role. Large numbers of sexual partners, unpro-
tected anal sex and practices such as fisting, rectal
drug use and the use of sex toys and enemas are
further risk factors which have been associated
with LGV proctitis [10].
This new epidemic has necessitated the devel-
opment of trustworthy laboratory techniques for
diagnostic and screening purposes. Although nu-
cleic acid amplification tests are well established in
the diagnosis of urogenital CT infections in both
males and females, culture is still regarded as stan-
dard for testing at extragenital sites. Concerns
have been raised about the specificity of nucleic
acid amplification tests in low-prevalence settings,
but studies in recent years have shown that these
tests are much more sensitive than culture and
should be the method of choice for the detection
of CT at extragenital sites in MSM [23–25].
Zurich has not been spared by the recent out-
breaks, although up to now most cases seem to be
associated with outbreaks in other European
countries and no epidemiological connection be-
tween the observed cases has been established.
Some of the patients were treated with a sin-
gle dose of azithromycin or short courses (10 days)
of doxycycline for chlamydial infection before
typing was available, and the attending physician
learned about the serotype only afterwards. The
fact that no chlamydia could be detected in these
patients at follow-up may indicate that these treat-
ment regimens are sufficient for some cases, but
this hypothesis has not been formally tested. It
must be clearly stated that the current guidelines
for treatment of rectal LGV infection recommend
doxycycline 100 mg bid for 21 days.
Anorectal LGV infections may progress to
severe destructive changes with formation of gran-
ulomas, strictures, and perirectal abscesses. LGV
may be contributing to the epidemic of human
immunodeficiency virus infection by facilitating
transmission [26]. Recently sexually acquired reac-
tive arthritis (SARA) and conjunctivitis have been
reported as complications in a patient with LGV
proctitis [27]. LGV proctitis can be confused clin-
ically with other rectal STDs as well as non-infec-
tious enteropathies.A recent study identified LGV
as the third most frequent sexually transmitted in-
fection causative of proctitis in MSM, after gonor-
rhoea and HSV infection [26]. The diagnosis of
LGV proctitis is usually delayed and requires a
high index of clinical suspicion. Increased aware-
ness of this recently recognised problem in Euro-
pean communities of MSM, new forms of surveil-
lance and establishment of reliable diagnostic
tools are required to prevent avoidable complica-
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